Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

The New England Journal of Medicine
Mario CastroAriel Teper

Abstract

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma. We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos for 52 weeks. The primary end points were the annualized rate of severe asthma exacerbations and the absolute change from baseline to week 12 in the forced expiratory volume in 1 second (FEV1) before bronchodilator use in the overall trial population. Secondary end points included the exacerbation rate and FEV1 in patients with a blood eosinophil count of 300 or more per cubic millimeter. Asthma control and dupilumab safety were also assessed. The annualized rate of severe asthma exacerbations was 0.46 (95% confidence interval [CI], 0.39 to 0.53) among patients assigned to 200 mg of dupilumab every 2 weeks and 0.87 (95% CI, 0.72 to 1.05) among those assigned to a matched placebo, for a 47.7% lower rate with dupilumab than with placebo (P<0.001); similar results were seen with the dupilumab dose of 300 mg every ...Continue Reading

References

Oct 22, 1998·The New England Journal of Medicine·P LangeG Jensen
Jul 17, 2004·American Journal of Respiratory and Critical Care Medicine·Eric D BatemanUNKNOWN GOAL Investigators Group
Apr 13, 2005·Respiratory Medicine·Elizabeth F JuniperElisabeth Ståhl
May 23, 2006·Respiratory Medicine·Stephen P PetersColin Reisner
Jun 19, 2009·American Journal of Respiratory and Critical Care Medicine·Helen K ReddelUNKNOWN American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations
Feb 23, 2010·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Juan Luis Rodriguez HermosaJose Luis Alvarez-Sala Walther
Jan 22, 2013·Nature Reviews. Drug Discovery·Patricia C Fulkerson, Marc E Rothenberg
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Lynn E MacdonaldAndrew J Murphy
Dec 24, 2014·Nature Reviews. Immunology·John V Fahy
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Dec 31, 2016·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·D RobinsonP Nair
Mar 10, 2017·Expert Review of Clinical Immunology·Namita A GandhiNeil M H Graham
Feb 16, 2018·The European Respiratory Journal·Hanneke CoumouElisabeth H Bel
May 22, 2018·The New England Journal of Medicine·Klaus F RabeAriel Teper

❮ Previous
Next ❯

Citations

May 22, 2018·The New England Journal of Medicine·Jeffrey M Drazen, David Harrington
May 22, 2018·The New England Journal of Medicine·Klaus F RabeAriel Teper
Jul 12, 2018·American Journal of Respiratory and Critical Care Medicine·Fernando Holguin
Nov 14, 2018·Current Opinion in Pulmonary Medicine·David L Peloza, Daniel J Jackson
Dec 5, 2018·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Khalid Al EfraijJ Mark FitzGerald
Dec 5, 2018·Expert Opinion on Investigational Drugs·Giancarlo MaroneGilda Varricchi
Nov 18, 2018·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Jocelyne JustFlore Amat
Oct 6, 2018·Allergy·Ibon Eguiluz-GraciaMaria J Torres
Jan 12, 2019·Expert Opinion on Drug Metabolism & Toxicology·Diego BagnascoGiorgio Walter Canonica
Feb 7, 2019·Expert Opinion on Pharmacotherapy·Dhuha Al-SajeeGail M Gauvreau
Feb 13, 2019·British Journal of Hospital Medicine·Hitasha Rupani, Anoop J Chauhan
Dec 19, 2018·American Journal of Respiratory and Critical Care Medicine·J Michael RamsahaiPeter A B Wark
Dec 12, 2018·American Journal of Respiratory and Critical Care Medicine·Mary Clare McGregorMario Castro
Nov 9, 2018·American Journal of Respiratory and Critical Care Medicine·Christian Taube, Sebastian Reuter
Feb 15, 2019·Vaccines·John Foerster, Aleksandra Molęda
Jan 17, 2019·Current Opinion in Allergy and Clinical Immunology·Elise M SlobMariëlle W Pijnenburg
Dec 14, 2018·The European Respiratory Journal·Marlies S WijsenbeekVincent Cottin
Dec 14, 2018·The European Respiratory Journal·Rahul ShrimankerCiléin Kearns
Feb 15, 2019·The European Respiratory Journal·Parameswaran Nair, Paul M O'Byrne
Nov 18, 2018·The European Respiratory Journal·William W BusseGene Colice
Mar 13, 2019·JAMA : the Journal of the American Medical Association
Feb 7, 2019·American Journal of Respiratory and Critical Care Medicine·Salman SiddiquiNizar N Jarjour
Apr 4, 2019·Frontiers in Pediatrics·Andrew Bush
Apr 18, 2019·JAMA Dermatology·Aleksi J Hendricks, Vivian Y Shi
Mar 10, 2019·The British Journal of Dermatology·B AkinladeA Wollenberg
Jun 21, 2019·Immunotherapy·Alice Grey, Constance H Katelaris
May 3, 2019·The European Respiratory Journal·Paul O'ByrnePeter Lange
May 31, 2019·Current Opinion in Allergy and Clinical Immunology·Jorien van der SchaftDeepak M W Balak
Jun 7, 2019·Current Opinion in Allergy and Clinical Immunology·Sara M Assaf, Nicola A Hanania
Jul 4, 2019·Allergy·P Jane McDowell, Liam G Heaney
Jul 30, 2019·European Journal of Immunology·Lorenzo CosmiFrancesco Annunziato
Aug 8, 2019·Expert Review of Clinical Immunology·Enrico HefflerGiorgio Walter Canonica
Jun 21, 2019·International Journal of Molecular Sciences·Mayumi SaekiOsamu Kaminuma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.